IMD 2128
Alternative Names: IMD-2128Latest Information Update: 08 Jul 2026
At a glance
- Originator Shanghai Affinity Biopharmaceutical
- Class 2 ring heterocyclic compounds; Antibodies; Antineoplastics; Cyclic ethers; Drug conjugates; Furans; Immunoconjugates; Ketones; Macrocyclic compounds
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 17 Apr 2026 Pharmacodynamics, pharmacokinetics and adverse events data from a preclinical trial in Solid tumours presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
- 04 Jul 2024 Preclinical trials in Solid tumours in China (Parenteral), prior to July 2024 (Shanghai Affinity Biopharmaceutical pipeline, July 2024)